|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Correspondence: Cynthia Dunbar, MD, Hematology Branch, NIH, Building 10, Room 7C103, 9000 Rockville Pike, Bethesda, MD 20892; phone (301) 496-1434; fax (301) 496-8396; dunbarc{at}nhlbi.nih.gov
Abstract
Over the past decade, success in the treatment of serious genetic disorders via gene therapy was finally achieved. However, this progress was tempered by the occurrence of serious adverse events related to vector integration into the genome and activation of adjacent proto-oncogenes. Investigators are now focused on retaining the clinical potential of integrating vectors while decreasing the risk of insertional mutagenesis.
![]()
CiteULike
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |